Engineered biosynthetic pathway for sialic acid analogs and its use for the development of anti-infectives
There is clearly an unmet need for anti-influenza drugs that are more effective than those currently available, and ideally that are effective against various strains of influenza and that are not prone to the development of resistance. The unique features of the NRC-IBS technology, with its anticip...
| Main Authors: | , |
|---|---|
| Format: | Other/Unknown Material |
| Language: | English |
| Published: |
National Research Council of Canada
2010
|
| Subjects: | |
| Online Access: | https://nrc-publications.canada.ca/eng/view/ft/?id=0c36bca9-da1a-48cd-9eff-b526aceb2556 https://nrc-publications.canada.ca/eng/view/object/?id=0c36bca9-da1a-48cd-9eff-b526aceb2556 https://nrc-publications.canada.ca/fra/voir/objet/?id=0c36bca9-da1a-48cd-9eff-b526aceb2556 |
| Summary: | There is clearly an unmet need for anti-influenza drugs that are more effective than those currently available, and ideally that are effective against various strains of influenza and that are not prone to the development of resistance. The unique features of the NRC-IBS technology, with its anticipated efficacy against numerous strains, possibly including avian flu, will enable it to compete effectively against such products. We also note that the market is quite large, and is likely to continue to grow over the coming years. The technology may also result in the development of agents against other viral infections, and against bacterial infections. Peer reviewed: Yes NRC publication: Yes |
|---|